Trial reportActa psychiatrica Scandinavica2015
Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.
Trial report in Acta psychiatrica Scandinavica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Effectiveness of unguided web-based interventions for the treatment of depressive symptoms in improving the quality of life: a meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Pooled it
- The risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis.BMC psychiatry · 2025Pooled it
- The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.Epidemiology and psychiatric sciences · 2024Pooled it
- Effect of Probiotic Supplementation on Gut Microbiota in Patients with Major Depressive Disorders: A Systematic Review.Nutrients · 2023Pooled it
- Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.BMC psychiatry · 2023Trial
- Modified Xiaochaihu Decoction Combined with Mirtazapine in the Treatment of Persistent Depression: A Pilot Randomized Controlled Trial.Contrast media & molecular imaging · 2022Trial
- A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance.Clinical and translational science · 2022Trial
- Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Trial
- Cognitive Therapy vs. Short-Term Dynamic Psychotherapy in a Community Mental Health Setting: A Preliminary Analysis of Effects in Several Severity Domains.Clinical psychology & psychotherapyTrial
- NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- A Secondary Analysis of Longitudinal Pilot-Study Data Investigating the Associations Between Health-Related Quality of Life and Executive Functions in Remitted Major Depressive Disorder and Developments Two-Years Following Cognitive Training.Scandinavian journal of psychology · 2026Article
- The effects of rTMS on self-reported quality of life in younger and older adults with major depressive disorder.Psychological medicine · 2025Article
- Article
- Quality of Life and Caregiver Burden in Adult ADHD, Major Depressive Disorder, and Personality Disorders: A Cross-Sectional Study.The Psychiatric quarterly · 2025Article
- The trajectory of depressive symptoms and the association with quality of life and suicidal ideation in patients with major depressive disorder.BMC psychiatry · 2025Article
- Clinical and Treatment Characteristics of 3795 Adults Consecutively Hospitalized for Major Depressive Disorder in the OASIS-D Study.Depression and anxiety · 2025Article
- Dietary magnesium intake affects the association between dietary vitamin A and depression: a cross-sectional study.Frontiers in nutrition · 2025Article
- The Association Between Medication Adherence, Internalized Stigma and Social Support Among Outpatients with Major Depressive Disorder in a Malaysian Hospital: A Cross-Sectional Study.Psychology research and behavior management · 2025Article
- Impact of Emotional Blunting on Patient Social Function and Depressive Symptoms: A Post Hoc Analysis of a Web-Based Survey in Japanese Patients with Major Depressive Disorder.Neuropsychiatric disease and treatment · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThis study examines the impact of major depressive disorder (MDD) and its treatment on quality of life (QOL).
methodFrom the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, we analyzed complete data of 2280 adult MDD out-patients at entry/exit of each level of antidepressant treatments and after 12 months of entry to follow-up. QOL was measured using the QOL Enjoyment and Satisfaction Questionnaire (Q-LES-Q). The proportions of patients scoring 'within-normal' QOL (within 10% of Q-LES-Q community norms) and those with 'severely impaired' QOL (>2 SD below Q-LES-Q community norms) were analyzed.
resultsBefore treatment, no more than 3% of MDD patients experienced 'within-normal' QOL. Following treatment, statistically significant improvements were detected; however, the proportion of patients achieving 'within-normal' QOL did not exceed 30%, with >50% of patients experiencing 'severely impaired' QOL. Although remitted patients had greater improvements compared with non-remitters, 32-60% continued to experience reduced QOL. 12-month follow-up data revealed that the proportion of patients experiencing 'within-normal' QOL show a statistically significant decrease in non-remitters.
conclusionSymptom-focused treatments of MDD may leave a misleading impression that patients have recovered when, in fact, they may be experiencing ongoing QOL deficits. These findings point to the need for investigating specific interventions to ameliorate QOL in MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.